In Vitro Susceptibilities of Mycoplasma hominis to Six Fluoroquinolones as Determined by E Test | Zendy

Ken B. Waites | Zendy; Kay C. Canupp | Zendy; George E. Kenny | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Susceptibilities of Mycoplasma hominis to Six Fluoroquinolones as Determined by E Test

Author(s) -

Ken B. Waites,

Kay C. Canupp,

George E. Kenny

Publication year - 1999

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.43.10.2571

Subject(s) - trovafloxacin , sparfloxacin , moxifloxacin , mycoplasma hominis , microbiology and biotechnology , agar dilution , ciprofloxacin , levofloxacin , agar dilution method , ofloxacin , antibacterial agent , mycoplasmataceae , gatifloxacin , lomefloxacin , minimum inhibitory concentration , biology , chemistry , mycoplasma , antibiotics , mollicutes

Twenty isolates of Mycoplasma hominis were tested for their susceptibility to six fluoroquinolones by the E test. The MICs at which 90% of the isolates were inhibited (in micrograms per milliliter) were as follows: sparfloxacin, 0.031; clinafloxacin, moxifloxacin, and trovafloxacin, 0.063; levofloxacin, 0.25; and ciprofloxacin, 0.5. Increasing the amount of inoculum or incubation in CO(2) elevated MICs by </=1 dilution. E tests produce fluoroquinolone MICs comparable to those obtained by agar and microbroth dilution for M. hominis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research